GLP-1 analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Purity specification (research grade) | Greater than 95 percent by HPLC | Area percent at 220 nm; method dependent |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical |
| Residual water | Reported by Karl Fischer titration | Affects peptide content calculation |
| Common synonyms | GLP-1 analog; GLP-1 receptor agonist peptide | Naming varies across catalogs |
| Container material | Low-binding polypropylene | Reduces adsorption at low concentration |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Preservation of the Church's autonomy and rights, as accepted by the constitution. Defence against any attack on the independence of Church bodies, on the development of religious life and on the practice of Christian charity. Effectual implementation of parity for recognised denominations. Rejection of any attempt to de-Christianise marriage. Preservation or founding of denominational schools. There were also more general demands such as for a more federal, decentralised state, a limitation of state expenditure, a just distribution of taxes, the financial strengthening of the middle classes and the legal "removal of such evil states, that threaten the worker with moral or bodily ruin". With such a manifesto, the number of Catholic representatives in the Prussian Diet rose considerably. In December 1870, they formed a new "Centre" faction, also called the "Constitution Party" to emphasise its adherence to constitutional liberties. Three months later, early in 1871, the Catholic representatives to the new national parliament, the Reichstag, also formed a "Centre" faction. The party not only defended the Church's liberties, but also supported representative government and minority rights in general, in particular those of German Poles, Alsatians, and Hannoverians. The Centre's main leader was the Hannoverian advocate Ludwig Windthorst and other major figures included Karl Friedrich von Savigny, Hermann von Mallinckrodt, Burghard Freiherr von Schorlemer-Alst, the brothers August Reichensperger and Peter Reichensperger, Franz von Ballestrem and Georg Count Hertling.
In biochemistry, flavin adenine dinucleotide (FAD) is a redox-active coenzyme associated with various proteins, which is involved with several enzymatic reactions in metabolism. A flavoprotein is a protein that contains a flavin group, which may be in the form of FAD or flavin mononucleotide (FMN). Many flavoproteins are known: components of the succinate dehydrogenase complex, α-ketoglutarate dehydrogenase, and a component of the pyruvate dehydrogenase complex. FAD exists in two common oxidation states, the fully oxidized form (FAD) and the fully reduced, dihydrogenated form, FADH2. Other oxidation states also exist, including the N-oxide and semiquinone states. FAD, in its fully oxidized form, accepts two electrons and two protons to become FADH2. The semiquinone (FADH·) can be formed by either reduction of FAD or oxidation of FADH2 by accepting or donating one electron and one proton, respectively. Some proteins, however, generate and maintain a super oxidized form of the flavin cofactor, the flavin-N(5)-oxide.
In the late 1920s, Pauling began publishing papers on the nature of the chemical bond. Between 1937 and 1938, he took a position as George Fischer Baker Non-Resident Lecturer in Chemistry at Cornell University. While at Cornell, he delivered a series of nineteen lectures and completed the bulk of his famous textbook The Nature of the Chemical Bond. It is based primarily on his work in this area that he received the Nobel Prize in Chemistry in 1954 "for his research into the nature of the chemical bond and its application to the elucidation of the structure of complex substances". Pauling's book has been considered "chemistry's most influential book of this century and its effective bible". In the 30 years after its first edition was published in 1939, the book was cited more than 16,000 times. Even today, many modern scientific papers and articles in important journals cite this work, more than seventy years after the first publication. Part of Pauling's work on the nature of the chemical bond led to his introduction of the concept of orbital hybridization. While it is normal to think of the electrons in an atom as being described by orbitals of types such as s and p, it turns out that in describing the bonding in molecules, it is better to construct functions that partake of some of the properties of each.
==== 2005 Tbilisi grenade attack ==== On May 10, 2005, while President Bush was giving a speech in Freedom Square, Vladimir Arutyunian, a native Georgian who was born to a family of ethnic Armenians, threw a live Soviet-made RGD-5 hand grenade toward the podium. It landed in the crowd about 61 feet (19 m) from the podium after hitting a girl, but it did not detonate because a red tartan handkerchief was wrapped tightly around it, preventing the safety lever from detaching. Georgian president Mikheil Saakashvili was seated nearby. After escaping that day, Arutyunian was arrested in July 2005. During his arrest, he killed an Interior Ministry agent. He was convicted in January 2006 and given a life sentence.
=== The renaissance: the hammerhead ribozyme and the group I intron: P4-6 === For a considerable time following the first tRNA structures, the field of RNA structure did not dramatically advance. The ability to study an RNA structure depended upon the potential to isolate the RNA target. This proved limiting to the field for many years, in part because other known targets—i.e., the ribosome—were significantly more difficult to isolate and crystallize. Further, because other interesting RNA targets had simply not been identified, or were not sufficiently understood to be deemed interesting, there was simply a lack of things to study structurally. As such, for some twenty years following the original publication of the tRNAPHE structure, the structures of only a handful of other RNA targets were solved, with almost all of these belonging to the transfer RNA family. This unfortunate lack of scope would eventually be overcome largely because of two major advancements in nucleic acid research: the identification of ribozymes, and the ability to produce them via in vitro transcription. Subsequent to Tom Cech's publication implicating the Tetrahymena group I intron as an autocatalytic ribozyme, and Sidney Altman's report of catalysis by ribonuclease P RNA, several other catalytic RNAs were identified in the late 1980s, including the hammerhead ribozyme. In 1994, McKay et al. published the structure of a 'hammerhead RNA-DNA ribozyme-inhibitor complex' at 2.6 Ångström resolution, in which the autocatalytic activity of the ribozyme was disrupted via binding to a DNA substrate.
Sources: en.wikipedia.org
The HTU or Hydro Thermal Upgrading process appears similar to the first stage of the TCC process. A demonstration plant is due to start up in The Netherlands said to be capable of processing 64 tons of biomass (dry basis) per day into oil.
Consequently, protein degradation did not represent anymore the end of the biological function of proteins, but rather the beginning of a yet unexplored side of the biology of the cells. A number of intra- or extracellular proteases release protein fragments endowed with essential biological activities. These hydrolytic processes could be carried out by proteases such as Proteasomes, Proprotein Convertases, Caspases, Rennin and Kallikreins. Among the products released by the non-lysosomal proteases are the bioactive oligopeptides such as hormones, neuropeptides and epitopes that, once released, could be modulated in their biological activities by specific peptidases, which promote the trimming, conversion and/or inactivation of the bioactive oligopeptides.
Again there are a few anomalies along the way: for example, as single atoms neither actinium nor thorium actually fills the 5f subshell, and lawrencium does not fill the 6d shell, but all these subshells can still become filled in chemical environments. For a very long time, the seventh row was incomplete as most of its elements do not occur in nature. The missing elements beyond uranium started to be synthesized in the laboratory in 1940, when neptunium was made. (However, the first element to be discovered by synthesis rather than in nature was technetium in 1937.) The row was completed with the synthesis of tennessine in 2009 (the last element oganesson had already been made in 2002), and the last elements in this seventh row were given names in 2016.
=== Unemployment === Unemployment has been shown to hurt an individual's emotional well-being, self-esteem, and more broadly their mental health. Increasing unemployment has been shown to have a significant impact on mental health, predominantly depressive disorders. This is an important consideration when reviewing the triggers for mental health disorders in any population survey. According to a 2009 meta-analysis by Paul and Moser, countries with high income inequality and poor unemployment protections experience worse mental health outcomes among the unemployed.
Sources: en.wikipedia.org
Sir Joseph John Thomson (18 December 1856 – 30 August 1940) was a British physicist. He received the 1906 Nobel Prize in Physics "in recognition of the great merits of his theoretical and experimental investigations on the conduction of electricity by gases." In 1897, he showed that cathode rays were composed of previously unknown negatively charged particles (now called electrons), which he calculated must have bodies much smaller than atoms and a very large charge-to-mass ratio. The electron was the first subatomic particle to be discovered. Thomson is credited with finding the first evidence for isotopes of a stable (non-radioactive) element in 1912, as part of his exploration into the composition of canal rays (positive ions). His experiments to determine the nature of positively charged particles, with Francis William Aston, were the first use of mass spectrometry and led to the development of the mass spectrograph. Thomson was an influential teacher, and seven of his students went on to win Nobel Prizes: Ernest Rutherford (Chemistry 1908), Lawrence Bragg (Physics 1915), Charles Barkla (Physics 1917), Francis Aston (Chemistry 1922), Charles Thomson Rees Wilson (Physics 1927), Owen Richardson (Physics 1928) and Edward Appleton (Physics 1947). His son, George Paget Thomson, shared the 1937 Nobel Prize in Physics with Clinton Davisson "for their experimental discovery of the diffraction of electrons by crystals".
== Research == Later, nelotanserin was repurposed for the treatment of Lewy body dementia (LBD) by Axovant Sciences (now Sio Gene Therapies). In late 2018, the company announced that while nelotanserin was generally well-tolerated by LBD patients in a small Phase 2 clinical trial for the treatment of REM sleep behavior disorder (RBD) and there were positive indications on some secondary trial outcomes such as sleep diaries and some polysomnogram sleep parameters, the drug failed to meet its primary endpoint of reducing the frequency of RBD episodes and would be discontinued.
== Deaths == 1 January – Frank McGarvey, Scottish footballer (St Mirren, Celtic, national team) (b. 1956) 18 March – Robert Lindsay, 29th Earl of Crawford, Scottish peer, MP (1955–1974) and Minister of State for Defence (1970–1972) (b. 1927) 21 March Willie Bell, Scottish footballer (Leeds United, national team) and manager (Birmingham City) (b. 1937) John Smith, Baron Kirkhill, Scottish peer, Lord Provost of Aberdeen (1971–1975) and Minister of State for Scotland (1975–1978) (b. 1930) 1 April – Ken Buchanan, professional boxer who became undisputed world lightweight champion in 1971 (b. 1945) 8 April – Bob Heatlie, Scottish songwriter ("Japanese Boy", "Cry Just a Little Bit", "Merry Christmas Everyone") and record producer (b. 1946). 30 April – Elizabeth Scott, Duchess of Buccleuch, wife of Richard Scott, 10th Duke of Buccleuch (b. 1954) 10 May – Hugo Burge, internet entrepreneur and owner of Marchmont House (b. 1972) 15 June – Gordon McQueen, Scottish footballer (Leeds United, Manchester United, national team) and manager. (b. 1953) 21 June – Winnie Ewing, Scottish politician (MP (1967–1979), MEP (1979–1999), MSP (1999–2003), President of the Scottish National Party (1987–2005)) (b. 1929) 26 June Craig Brown, Scottish professional footballer and football manager. (b. 1940) David Ogilvy, 13th Earl of Airlie, Scottish peer and Lord Chamberlain (1984–1997) (b. 1926) 2 July – Greig Oliver, 58, rugby union player. 6 September – John Cairney, Scottish actor (A Night to Remember, Cleopatra, Jason and the Argonauts), author and painter. (b.
Sources: en.wikipedia.org
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.
Each cycle exposes the peptide to ice-liquid interfaces where unfolding and aggregation can occur. Aggregates may not redissolve and can alter measured activity. Aliquoting before the first freeze reduces the number of cycles any single portion experiences.
It usually reports purity by HPLC, identity by mass spectrometry, peptide content, appearance, and residual moisture or counterion content. The analytical method behind each value should be stated. Acceptance criteria are set by the supplier or the buyer's specification.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.